A Study of Hospital-at-Home for People Receiving Tarlatamab
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
Treatment plan of commercially available tarlatamab monotherapy as standard of care
Patients must be 18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status <2
Disqualifiers
Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.
Patients with baseline dementia or cognitive barriers
Uncontrolled arrhythmias
Caregiver deemed inappropriate by treating physician
Trial design
Design model
Parallel
Treatments tested in this trial
Hospital-at-Home/HAH
Other interventionAfter discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence
Treatment groups
70 Participants
are divided into 2 treatment groupsGroup A: Control ArmNo intervention 0 interventions
Group B: Hospital-at-Home/HAH Intervention ArmExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of inpatient hospital days
Evaluate whether HaH in combination with an enhanced oncology specific telemedicine platform is efficient by quantifying inpatient hospital days during the two 7-day periods (14 days total) after the tarlatamab infusions scheduled for C1D1 and C1D8
Time frame
14 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov